Biomaterial Database

Prognostic factors in multiple myeloma: role of beta 2-microglobulin and thymidine kinase. 1993

H Diem, and A Fateh-Moghadam, and R Lamerz

Institut für Klinische Chemie, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.

Serum beta 2-microglobulin, serum thymidine kinase, and commonly used prognostic parameters were investigated for their prognostic value in a well-defined group of patients with multiple myeloma (n = 207). Multivariate analysis showed hemoglobin to be the parameter of strongest prognostic value. Only albumin, serum beta 2-microglobulin and serum thymidine kinase added further prognostic information. When tested for efficiency in recognizing patients with poor (average survival time < 1 year) and good (average survival time > 5 years) prognosis, serum beta 2-microglobulin was best (80%), followed by total urinary protein (78%), hemoglobin (76%), and albumin (75%).

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009101	Multiple Myeloma	A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.	Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011379	Prognosis	A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.	Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002455	Cell Division	The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.	M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000368	Aged	A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available.	Elderly
D000369	Aged, 80 and over	Persons 80 years of age and older.	Oldest Old

Related Publications

H Diem, and A Fateh-Moghadam, and R Lamerz

Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.

January 1990, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,

H Diem, and A Fateh-Moghadam, and R Lamerz

[Prognostic significance of beta-2-microglobulin in multiple myeloma].

January 1996, Voprosy onkologii,

H Diem, and A Fateh-Moghadam, and R Lamerz

[Prognostic effect of beta 2-microglobulin in multiple myeloma].

November 1992, Medicina clinica,

H Diem, and A Fateh-Moghadam, and R Lamerz

[Prognostic importance of beta-2-microglobulin in multiple myeloma].

January 1992, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,

H Diem, and A Fateh-Moghadam, and R Lamerz

[Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].

November 1985, Revue du rhumatisme et des maladies osteo-articulaires,